

Date and Time: *Thursday 19th and Friday 20th June 2014*
10:00 – 16:30

Minutes: Draft

Guideline Development Group Meeting **Diabetes in children and young people guideline update**

Place: *Royal College of Obstetricians and Gynaecologists*
London

Present:

Jerry Wales (Chair) (JW)	(Present for notes 1 – 21)
Francesca Annan (FA)	(Present for notes 1 – 21)
Jo Dalton (JD)	(Present for notes 1 – 21)
Jacqui Double (JDo)	(Present for notes 1 – 21)
Julie Edge (JE)	(Present for notes 1 – 21)
Nikhil Gokani (NG)	(Present for notes 1 – 21)
William Lamb (WL)	(Present for notes 1 – 21)
Carol Metcalfe (CM)	(Present for notes 1 – 21)

In attendance:

NCC-WCH staff:		
Sarah Bailey (SB)		(Present for notes 1 – 9)
Yelan Guo (YG)		(Present for notes 12 – 21)
Juliet Kenny (JK)		(Present for notes 1 – 21)
Paul Jacklin (PJ)		(Present for notes 10 – 11)
Moira Mugglestone (MM)		(Present for notes 1 – 21)
Stephen Murphy (SM)		(Present for notes 12 – 21)
Amy Wang (AW)		(Present for notes 1 – 11)
NICE attendees:		
Oliver Bailey		(Present for notes 1 – 21)

Observers:

None		
------	--	--

Notes

Day 1

1. JW welcomed the group to day 1 of the tenth meeting of this guideline development group (GDG). Apologies were received from Sarah Eaton and Zosia Beckles.
2. JW asked all the GDG members and other attendees to declare any new interests that they had accrued since GDG 9 and reiterate any interests declared previously that were relevant to the meeting agenda.

FA

Personal pecuniary interest

Received funding from Eli Lilly for speaking at the Eli Lilly National Paediatric Diabetes Meeting in May 2014 on topics relating to the management of diabetes that were not specific to the scope of the guideline (fat and protein counting and exercise). Received funding to cover travel and accommodation expenses from the International Society for Paediatric and Adolescent Diabetes (ISPAD) to attend and speak as an expert panel member on the management of diabetes at the 40th ISPAD conference in Toronto, Canada in September 2014.

JE

Non-personal pecuniary:

Holds managerial responsibility for departmental funding from Advanced Therapeutics, Aventis, Novo Nordisk and Roche for sponsorship of educational meetings in 2014.

Personal non-pecuniary interest

Attended a half-day training course organised by Medtronic about continuous intravenous insulin therapy pumps.

NG

Personal non-pecuniary interest

Member of Royal College of Physicians joint specialty committee on endocrinology and diabetes.

WL

Personal pecuniary interest:

Received payment for medico-legal work (expert testimony and a report) in a case pertaining to paediatric diabetes care that was not specific to the scope of the guideline (neglect).

CM

Personal pecuniary interest:

Received funding from Novo Nordisk to attend the Diabetes UK annual Professional Conference in March 2014 and from Eli Lilly to attend the Eli Lilly National Paediatric Diabetes Meeting in May 2014.

No other declarations of interest were received from the GDG members or the other attendees. It was agreed that no interests declared at the meeting or previously warranted exclusion of any GDG members from discussions of evidence or formulation of recommendations at the meeting.

3. The minutes from GDG 9 were agreed. The confirmed minutes from the previous two diabetic ketoacidosis (DKA) subgroup meetings were presented for information.
4. SB presented the evidence for monitoring for hypertension in children and young people with type 2 diabetes. The group discussed the findings of the review.
5. JW led the group through the process of interpreting the evidence and drafting recommendations for hypertension in children and young people with type 2 diabetes. Notes were made live on screen.
6. SB presented the evidence for monitoring for dyslipidaemia in children and young people with type 2 diabetes. The group discussed the findings of the review.
7. JW led the group through the process of interpreting the evidence and drafting recommendations for monitoring for dyslipidaemia in children and young people with type 2 diabetes. The group discussed the findings of the review. Notes were made live on screen.
8. SB presented the evidence for HbA_{1c} targets for children and young people with type 1 diabetes. The group discussed the findings of the review.
9. JW led the group through the process of interpreting the evidence and drafting recommendations for HbA_{1c} targets for children and young people with type 1 diabetes. Notes were made live on screen.
10. JE updated the group on the progress of the DKA subgroup. MM explained that a new review question on the management of cerebral oedema had been proposed and would be considered if possible within the current resources and timelines. AW presented the draft review protocol for the new review question on cerebral oedema. The group then discussed the protocol and notes were made live on screen.
11. PJ updated the group on progress with the health economics analysis for the topics of multiple daily injections versus mixed insulin in children and young people with type 1 diabetes and structured education for children and young people with type 1 diabetes. The IMS Core Diabetes Model was demonstrated live on screen and the group had the opportunity to ask questions and provide feedback.
Day 2
12. JW welcomed the group to day 2 of the meeting. No further interests were declared by attendees joining the meeting on the second day.
13. YG presented the evidence for monitoring for nephropathy in children and young people with type 1 diabetes. The group discussed the findings of the review.

14. JW led the group through the process of interpreting the evidence and drafting recommendations for monitoring for nephropathy in children and young people with type 1 diabetes. Notes were made live on screen.
15. YG presented the evidence for monitoring for nephropathy in children and young people with type 2 diabetes. The group discussed the findings of the review.
16. JW led the group through the process of interpreting the evidence and drafting recommendations for monitoring for nephropathy in children and young people with type 2 diabetes. Notes were made live on screen.
17. SM gave feedback to the group from the Diabetes Oversight Group (DOG) meetings that were held on 20th March and 9th June 2014 and the group discussed issues arising from the feedback.
18. YG presented the evidence identified in the rerun searches for structured education for children and young people with type 1 diabetes. The group discussed the findings of the review.
19. JW led the group through the process of interpreting the additional evidence and redrafting the recommendations for structured education for children and young people with type 1 diabetes. Notes were made live on screen.
20. JK outlined the aims for the next two GDG meetings and the deadlines and processes leading up to submission of the guideline for stakeholder consultation and publication. The date of the post-consultation GDG was agreed.
21. There were no items of other business. JW thanked the group for attending and closed the meeting.

Date, time and venue of the next meeting

Monday 22nd and Tuesday 21st July 10:00–16:30 at the Royal College of Obstetricians and Gynaecologists, London